Physician profile
Norman B Turowsky
NPI 1720074057
$823.16
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $217 · 2021: $143 · 2022: $28.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $112.58 | 2019-2020 | |
| Abbvie INC. | $108.77 | 2019-2020 | |
| Abbott Laboratories | $104.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $100.48 | 2019-2021 | |
| Novo Nordisk INC | $96.96 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $76.90 | 2019-2020 | |
| Amarin Pharma, INC. | $53.54 | 2019-2020 | |
| Insulet Corporation | $35.40 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.35 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.98 | 2020 | |
| Allergan, INC. | $19.05 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $16.32 | 2021 | |
| Dexcom, INC. | $15.38 | 2021 | |
| Lilly USA, LLC | $14.86 | 2019 | |
| Aytu Biopharma, INC. | $14.18 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Turowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.